Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition composed of arsenic trioxide and Nandina domestica, its preparation method and its application

A technology of arsenic trioxide and Nantian bamboo, which is applied in the field of medicine, can solve the problems of restricting the application of this kind of medicine and unsafety

Inactive Publication Date: 2012-02-01
JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, clinical medication is very unsafe, which greatly limits the application of this class of drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition composed of arsenic trioxide and Nandina domestica, its preparation method and its application
  • Pharmaceutical composition composed of arsenic trioxide and Nandina domestica, its preparation method and its application
  • Pharmaceutical composition composed of arsenic trioxide and Nandina domestica, its preparation method and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] The acute toxicity comparison test of the pharmaceutical composition and the original drug of arsenic trioxide:

[0012] The improved Cole's method was used to carry out the oral acute toxicity comparison test in mice, and the results showed (see Table 1): the LD50 of the pharmaceutical composition was greater than the LD50 of the original drug of arsenic trioxide, and the growth status of the animals was relatively better.

[0013] Table 1. Results of oral acute toxicity comparison test in mice

[0014]

Embodiment 2

[0016] In vitro anti-tumor activity comparison test between the pharmaceutical composition and the original drug of arsenic trioxide:

[0017] Adopt the MTT method to measure the inhibitory effect of arsenic trioxide original drug and pharmaceutical composition on the growth of the following human tumor cells in vitro, and measure the half maximal killing concentration (IC 50 ), the positive control drug was cisplatin (Cisplatin).

[0018] Human tumor cell lines: promyelocytic leukemia cell line HL-60, multiple myeloma cell line U266, gastric cancer cell line MGC-803, lung cancer cell line A-549, liver cancer cell line SMMC-7721, cervical cancer cell line Hela, Breast cancer cell line MCF-7, nasopharyngeal cancer cell line HNE-1, ovarian cancer cell line Caov-3, laryngeal cancer cell line Hep-2, colon cancer cell line Col-6, kidney cancer cell line Re-01, prostate cancer cell line Cancer cell line PC-3, T cell lymphoma cell line Jurkat.

[0019] The test results show (see Ta...

Embodiment 3

[0023] Comparison of the anti-tumor activity of the pharmaceutical composition and the original drug of arsenic trioxide in vivo:

[0024] The inhibitory effect of the original arsenic trioxide drug and the pharmaceutical composition on the growth of S180 sarcoma in mice was compared, and the tumor inhibition rate was determined.

[0025] Kunming mice, half male and half female, weighing 20g±2g, were subcutaneously inoculated with S180 mouse tumor cells 4×10 in the right armpit of each mouse 6 , to establish the S180 mouse tumor transplantation model. They were randomly divided into a normal saline group, a positive control group, and a high, medium and low dose administration group, with 10 rats in each group. 24 hours after inoculation, intragastric administration was started. The positive control group was given etoposide (VP-16) 4 mg / kg, and the treatment group was given high, medium and low doses of corresponding drugs, once a day for 10 consecutive days. The animals we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition composed of arsenic trioxide and Nandina domestica, which is characterized in that the pharmaceutical composition comprises the following bulk drugs by weight: 1 part of arsenic trioxide and 10-106 parts of Nandina domestica; and discloses a preparation method and an application of the pharmaceutical composition in preparing medicine for treating tumor.

Description

technical field [0001] The invention belongs to the field of medicaments, and in particular relates to a pharmaceutical composition compatible with arsenic trioxide and nantian bamboo, as well as its preparation and application. Background technique [0002] Arsenic trioxide (As 2 o 3 ), also known as arsenic, anhydrous arsenic acid, arsenous anhydride. Arsenic trioxide has significant physiological activity and obvious anti-tumor effect. It is clinically used to treat various cancers such as leukemia, liver cancer, esophageal cancer, gastric cancer, colon cancer, and oropharyngeal cancer. Currently, the clinical preparations include sodium arsenite chloride injection liquid, the main component of which is As 2 o 3 , is a colorless, slightly salty clear liquid, suitable for the treatment of acute promyelocytic leukemia. However, arsenic trioxide is a highly toxic drug, with a median lethal dose (LD50) of approximately 10 mg / kg (intravenous injection in mice) and 40 mg / k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/29A61P35/00A61P35/02A61K33/36
Inventor 刘建群张锐舒积成任晓静
Owner JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com